Barclays’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | – | Sell |
-6,169
| Closed | -$44K | – | 4619 |
|
2025
Q1 | $44K | Sell |
6,169
-2,703
| -30% | -$19.3K | ﹤0.01% | 3922 |
|
2024
Q4 | $196K | Sell |
8,872
-384
| -4% | -$8.48K | ﹤0.01% | 3532 |
|
2024
Q3 | $185K | Buy |
9,256
+6,129
| +196% | +$123K | ﹤0.01% | 3526 |
|
2024
Q2 | $54K | Sell |
3,127
-11,830
| -79% | -$204K | ﹤0.01% | 3647 |
|
2024
Q1 | $623K | Sell |
14,957
-2,696
| -15% | -$112K | ﹤0.01% | 2712 |
|
2023
Q4 | $443K | Buy |
17,653
+4,915
| +39% | +$123K | ﹤0.01% | 3070 |
|
2023
Q3 | $417K | Buy |
12,738
+9,809
| +335% | +$321K | ﹤0.01% | 2655 |
|
2023
Q2 | $170K | Buy |
+2,929
| New | +$170K | ﹤0.01% | 3167 |
|
2022
Q3 | – | Sell |
-3
| Closed | – | – | 4843 |
|
2022
Q2 | $0 | Sell |
3
-257
| -99% | – | ﹤0.01% | 4943 |
|
2022
Q1 | $14K | Hold |
260
| – | – | ﹤0.01% | 4420 |
|
2021
Q4 | $18K | Sell |
260
-70
| -21% | -$4.85K | ﹤0.01% | 3115 |
|
2021
Q3 | $52K | Sell |
330
-217
| -40% | -$34.2K | ﹤0.01% | 3378 |
|
2021
Q2 | $107K | Sell |
547
-161
| -23% | -$31.5K | ﹤0.01% | 3120 |
|
2021
Q1 | $183K | Buy |
708
+275
| +64% | +$71.1K | ﹤0.01% | 3151 |
|
2020
Q4 | $83K | Buy |
+433
| New | +$83K | ﹤0.01% | 3028 |
|
2020
Q3 | – | Sell |
-5
| Closed | -$1K | – | 3939 |
|
2020
Q2 | $1K | Buy |
+5
| New | +$1K | ﹤0.01% | 3747 |
|
2020
Q1 | – | Sell |
-585
| Closed | -$188K | – | 3950 |
|
2019
Q4 | $188K | Buy |
585
+390
| +200% | +$125K | ﹤0.01% | 3204 |
|
2019
Q3 | $74K | Buy |
+195
| New | +$74K | ﹤0.01% | 3549 |
|
2019
Q2 | – | Sell |
-8
| Closed | -$4K | – | 4462 |
|
2019
Q1 | $4K | Buy |
+8
| New | +$4K | ﹤0.01% | 4104 |
|
2018
Q4 | – | Sell |
-11
| Closed | -$3K | – | 4429 |
|
2018
Q3 | $3K | Buy |
11
+6
| +120% | +$1.64K | ﹤0.01% | 4150 |
|
2018
Q2 | $3K | Hold |
5
| – | – | ﹤0.01% | 4068 |
|
2018
Q1 | $22K | Buy |
+5
| New | +$22K | ﹤0.01% | 3819 |
|